Sanofi-Aventis China Funds Clinical Practice Guideline Program For Hypertension
This article was originally published in PharmAsia News
Executive Summary
China recently kicked off a clinician practice guideline initiative, which will be adopted by the Chinese Medical Association. Hosted by the China International Medical Foundation and funded by Sanofi-Aventis China, one program will establish an expert panel to study the use of Irbesartan to control hypertension. To help physicians solve common clinical problems and raise the success rate of hypertension control, international and domestic academic exchanges will be held for Chinese cardiovascular-related experts. Meanwhile, China will conduct a survey on hypertension drug applications across the country. (Click here for more - Chinese Language)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.